In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be “Yes”:

☐ Does the activity align with Pfizer’s areas of interest? *(listed on pages 2-10 of this document)*

☐ Is it a live* annual activity which serves as a platform for the exchange of new clinical and scientific information and reaches an international, national, or regional audience?

*Live CME/CE activities are defined as any activity which incorporates the opportunity for live real-time learner interaction such as live meetings, e-learning and live non-enduring web-casts/webinars

☐ Is this activity developed by your organization specifically for your professional members or constituents?

☐ Is the activity established part of your organization’s ongoing educational program? If not, if it is a new activity, is it clearly based on an assessment of the educational needs of your target audience?

<table>
<thead>
<tr>
<th>Application Cycle</th>
<th>To Submit Live Activity Must Start On or After</th>
<th>Decision Communicated By*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 1 - Feb 15</td>
<td>Apr 1</td>
<td>Mar 10</td>
</tr>
<tr>
<td>Mar 1 - Apr 15</td>
<td>July 1</td>
<td>June 1</td>
</tr>
<tr>
<td>June 1 - July 15</td>
<td>Oct 1</td>
<td>Sept 1</td>
</tr>
<tr>
<td>Sept 1 - Oct 1</td>
<td>Jan 1, 2019</td>
<td>Dec 1</td>
</tr>
</tbody>
</table>

If your activity is in….. Latest* Date to submit to Pfizer is….

<table>
<thead>
<tr>
<th>If your activity is in…..</th>
<th>Latest* Date to submit to Pfizer is….</th>
</tr>
</thead>
<tbody>
<tr>
<td>April, May or June 2018</td>
<td>February 15</td>
</tr>
<tr>
<td>July, August or September 2018</td>
<td>April 15</td>
</tr>
<tr>
<td>October, November or December 2018</td>
<td>July 15</td>
</tr>
<tr>
<td>January, February or March 2019</td>
<td>October 1</td>
</tr>
</tbody>
</table>

*This is the latest date to submit. Your request will be reviewed if submitted in an earlier cycle.

PLEASE NOTE THAT DUE TO A SCHEDULED SYSTEM UPDATE, NO NEW APPLICATIONS WILL BE ACCEPTED BETWEEN OCTOBER 1 AND DECEMBER 31

Questions? Email IGLC@pfizer.com

Revised April 2018
**Acromegaly**
Improve the knowledge base of health care providers, educators, and third party payers working in the area of acromegaly.

**Antidote Therapies and Emergency Care**
- Improve healthcare providers and policy makers understanding of antidote therapies and availability.
- Improve the care of patients exposed to treatable poisonings by:
  - Increasing awareness of the epidemiology of toxic exposures
  - Increasing awareness of treatment options

**Attention Deficit Hyperactivity Disorder (ADHD)**
Improve the healthcare providers’ understanding of the appropriate diagnosis, treatment and management of ADHD in children through to adulthood within the primary and specialty care settings.

**Biosimilars (Rheumatology, Gastroenterology, Nephrology, Oncology)**
- Support clinicians’ understanding of complex biosimilar concepts in order to facilitate meaningful discussion of these concepts with patients
- Support the prudent (safe and effective) use of biologic drugs by
  - Increasing awareness of the regulatory framework governing the approval and prescription of biosimilar drugs
  - Increasing awareness of the FDA purple book

**Cardiovascular Metabolic Risk**

**Cardiovascular Risk Reduction**
Increase the identification and effective treatment of patients with multiple risk factors for cardiovascular disease and stroke (e.g. hypertension, dyslipidemia, obesity, diabetes) by improving the understanding and clinical practice of healthcare professionals across the globe.

**Smoking Cessation**
Increase the number of patients who stop smoking by improving the frequency and effectiveness of smoking cessation intervention, including treatment, counseling and support, by healthcare providers.

*Questions? Email IGLC@pfizer.com*
Consumer Healthcare

**Dietary Supplements**
- Improve the healthcare provider’s ability to advise and counsel patients on the prevalence of nutritional gaps even amongst consumers with a healthy diet and the roles of MVMs designed to fill nutritional gaps.
- Increase the healthcare provider’s ability to advise and counsel patients on the importance of diet and nutrition, particularly in the areas of bone, muscle and joint health. To educate physicians on prevalence of osteoporosis and importance of maintaining mobility.

**Digestive Health**
- Improve the healthcare provider’s ability to counsel patients on the appropriate use of OTC PPIs, based on an accurate evaluation of safety and efficacy data as well as a clear understanding of mechanism of action.
- Increase the healthcare provider's knowledge of the benefit risk profile of over the counter medications available for the treatment of occasional to frequent heartburn and acid reflux.

**Immunity**
- Improve the healthcare provider’s understanding of the role of vitamins and minerals and other nutrients or nutrition in immunity.
- Improve the healthcare provider’s understanding of the contributing factors and their effects in maintaining a healthy immune system (sleep, energy, stress).
- Improve the healthcare provider’s understanding of impacts of acquired and humoral immune response with use of supplements/ingredients.

**Mobility**
- Improve the healthcare provider’s knowledge of non-pharmacologic treatment options for acute non-specific low back pain, with a particular focus on the effects of thermal therapies.
- Improve the healthcare provider’s knowledge of recommendations regarding use of non-pharmacologic treatment options as first line treatment for acute non-specific low back pain.

**Pain-Free Living**
- Improve the healthcare provider's knowledge of the benefit/risk profile of over-the-counter (OTC) medications available for the treatment of acute pain, and the importance of opioid-sparing treatment approaches.

**Questions? Email** [IGLC@pfizer.com](mailto:IGLC@pfizer.com)
• Improve the healthcare provider’s ability to counsel patients on the appropriate use of over-the-counter (OTC) analgesics, based on an accurate evaluation of efficacy data and safety data (especially cardiovascular, gastrointestinal, and hepatic safety), as well as a clear understanding of the mechanisms of action.

Inflammatory Skin Diseases

**Atopic Dermatitis**
Improve the care of patients manifesting atopic dermatitis (AD) by increasing healthcare provider knowledge of the disease state or unmet need and the emerging strategies for treatment of AD.

**Inflammatory Diseases such as Alopecia and Vitiligo**
For dermatologists and all healthcare professionals involved in the care and treatment of patients suffering from dermatologic conditions such as alopecia and vitiligo, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and mechanisms-of-action of new medicines for the treatment of dermatologic conditions.

**Psoriatic Arthritis**
• Improve the care of patients with psoriatic arthritis by increasing healthcare provider knowledge of: (1) the pathophysiology of psoriatic arthritis, (2) the co-management of psoriatic arthritis, (3) the unmet needs in treatment of psoriatic arthritis, and (4) the mechanism of action and clinical data regarding advanced therapies.
• Educate regarding the national and international guidelines for psoriatic arthritis

**Duchenne Muscular Dystrophy**
Close knowledge gaps regarding the progression of the pathophysiology and clinical manifestations.

**Friedreich’s Ataxia**
Improve the understanding of the progression of the pathophysiology and clinical manifestations.

**Gene Therapy**
Close knowledge gaps regarding gene therapy applications and clinical development and conduct of clinical trials.

**Growth Hormone Deficiency**
Improve the knowledge base of health care providers, educators, and third party payers working in the area of GHD.

Questions? Email IGLC@pfizer.com
**Hemophilia**
Facilitate enhanced coordination of care and communications between patients with clotting or bleeding disorders, including hemophilia, and their doctors, and ensure practitioners know how to safely treat and monitor these patients.

**Infectious Disease**

**Staphylococcus aureus**
- Increase understanding of the burden of Staphylococcus aureus infections in surgical populations
- Increase awareness of research of preventive vaccines for Staphylococcus aureus

**Clostridium difficile**
- Increase the understanding of the burden of Clostridium difficile infection.
- Increase awareness of ongoing research of preventative vaccines for Clostridium difficile infection

**Respiratory Syncytial Virus (RSV)**
- Increase understanding of burden of disease of RSV in infants, children and adults
- Increase understanding of immune response to RSV in infants, children and adults
- Increase awareness of ongoing research of preventative vaccines for RSV

**Group B Streptococcus (GBS)**
- Increase understanding of burden of disease of GBS in adults
- Increase understanding of immunological biomarkers for GBS infection in infants and adults
- Increase awareness of ongoing research of preventative vaccines for GBS

**Inflammatory bowel disease (IBD)**
Improve the care of patients with inflammatory bowel disease (IBD) by increasing healthcare provider knowledge of the emerging strategies for treatment of IBD.

**Lysosomal Storage Diseases**
Improve positive outcomes in patients with Lysosomal Storage Diseases by facilitating enhanced coordination of care and communication between multidisciplinary teams of healthcare professionals, ensuring practitioners know how to safely treat and monitor patients.

**Questions? Email** IGLC@pfizer.com
Metabolic Conditions

**Non-Alcoholic Steatohepatitis (NASH)**
The goals are to accelerate innovations in the diagnosis and treatment of NASH, and to improve evidence-based NASH education for health care providers.

**Myotonic Dystrophy (DM1)**
Improve the understanding of the progression of the pathophysiology and clinical manifestations.

Oncology

**Acute Lymphoblastic Leukemia (ALL)**
For hematologists, oncologists, transplant physicians, and all healthcare professionals involved in the care and treatment of patients with ALL, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and the potential use of novel targeted agents for the treatment of ALL.

**Acute Myeloid Leukemia (AML)**
For hematologists, oncologists, transplant physicians, and all healthcare professionals involved in the care and treatment of patients with AML, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and the potential use of novel targeted agents for the treatment of AML, either alone or in combination with chemotherapy.

**Breast Cancer**
For oncologists and all healthcare professionals involved in the care and treatment of patients with advanced or metastatic breast cancer, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and mechanisms-of-action of new medicines in particular advances in CDK 4/6 inhibition and PARP inhibition. Other topics of interest include optimizing clinical practice, understanding patient experiences and implementation of clinical pathways.

**Chronic Myelogenous Leukemia (CML)**
For hematologists, oncologists and all healthcare professionals involved in the care and treatment of patients with CML, increase awareness of the importance of long term safety with BCR-ABL TKI treatment, improve ability to select optimal treatment options, and individualize treatment and dosage based on each patient’s medical history and comorbidities (e.g. cardiovascular risk factors.)

*Questions? Email IGLC@pfizer.com*
Immuno-Oncology (IO)
For medical oncologists and all healthcare professionals involved in the care and treatment of patients with lung, bladder, ovarian, renal, or head & neck cancers:
- Increase understanding of the rationale for novel IO strategies such as anti-PD-1/PD-L1 therapy
- Increase awareness of when immunotherapy should be considered as a treatment option for patients to include selection, sequencing, and combinations
- Improve ability to manage associated IO treatment issues including side effects and progression

Non-Small Cell Lung Cancer (NSCLC)
For oncologists, pulmonologists, pathologists, surgeons, interventional radiologists, and all healthcare professionals involved in the care and treatment of patients with NSCLC, increase the awareness and understanding of the importance of treating patients based on the timely results of molecular testing (e.g. ALK, EGFR, ROS1) in order to optimize patient outcomes.

Renal Cell Carcinoma (RCC)
For oncologists, urologists and all healthcare professionals involved in the care and treatment of patients with advanced RCC, increase awareness of the evolving treatment landscape and clinical trial results, and also improve clinical competence in applying this information to patient care, especially with respect to sequencing, scheduling, dosing, adjuvant use, use of combination therapies, and management of side effects.

General Oncology - Basic Science and Clinical Research Interests
Through the academic exchange of research and ideas, enhance the discovery and translation of novel cancer therapies, increase scientific understanding of their mechanisms-of-action as well as the efficacy, safety, and potential clinical applicability. Topics of interest include antiangiogenesis, signal transduction, cytotoxic potentiators, tyrosine kinase inhibitors, checkpoint inhibitors, biosimilars, antibody drug conjugates, biomarkers, and immuno-oncology (IO) specific correlates of safety and efficacy. Also within IO there is particular interest in advancing the understanding of combinations of novel IO therapies with conventional, targeted, radiation, and existing IO therapies.

Pain
Chronic Pain assoc’d w/ Osteoarthritis; Chronic Low Back Pain (Pfizer/Lilly alliance)
Please see below under ‘Clinical Areas Reviewed through Joint Alliances/Partnerships.’

Pulmonary Arterial Hypertension (PAH)
Improve the understanding of the progression of the pathophysiology and clinical manifestations.

Questions? Email IGLC@pfizer.com
Rheumatoid Arthritis
- Improve the care of patients with rheumatoid arthritis (RA) by (1) increasing the knowledge of healthcare providers (HCPs) on the pathophysiology of RA, (2) the unmet needs in the treatment of rheumatoid arthritis, and (3) the mechanism of action and clinical data of current advanced therapies
- Address challenges in the management of patients with RA (such as vaccinations, comorbidities, treat to target, etc)

Sickle Cell
Improve healthcare provider’s knowledge of diagnosis and treatment of sickle cell disease and facilitate enhanced coordination of care and communication between patients with sickle cell disease and healthcare providers.

TTR Amyloidosis
Close knowledge gaps regarding the progression of the pathophysiology, clinical manifestations, and survival.

Vaccine Preventable Diseases
Improve immunization across the life span by addressing perceptions of society and healthcare providers related to pediatric, adolescent and adult immunizations.

Pneumococcal Disease
Improve the care of pediatric patients by:
- Highlighting the disparity between family physicians and pediatricians in adherence to recommended childhood vaccination schedule
- Addressing barriers to vaccination and series completion with a focus on lower education and socioeconomic groups and other under-immunized populations including rural and inner city settings as well as barriers to vaccination within the current medical system, including bureaucratic structure issues and HCP availability
- Assessing how barriers can be overcome in the current medical system where making changes in the practice is often difficult given the current bureaucratic structure of many practices and the demands on HCP time
- Exploring gaps in the healthcare system that negatively impact the burden of invasive pneumococcal disease and search for ways to minimize these gaps through educational programs

Improve the care of adult patients by
- Increasing the awareness of the changing epidemiology of pneumococcal pneumonia in adults
- Increasing the awareness and understanding of adult pneumococcal vaccination guidelines including the limitations of the guidelines
- Increasing the percentage of adults receiving national guideline and medical society recommended immunizations

Questions? Email IGLC@pfizer.com
Meningococcal Disease
Optimize the prevention of meningococcal disease by:

- Enhancing understanding of changing meningococcal epidemiology including mortality, morbidity and long term consequences of meningococcal disease
- Increasing awareness of the risk of meningococcal disease for all ages
- Improving meningococcal vaccine recommendation implementation and vaccine uptake including:
  - Risk of meningococcal disease by healthcare practitioners
  - Improving access to meningococcal vaccines
  - Understanding the preferences and choices of parents and adolescents towards meningococcal vaccines and disease prevention

Women’s Health
Support education where concepts, issues and advances in women’s reproductive and/or post-reproductive health care are discussed with a goal of improving individual and population health outcomes. Areas of particular interest include (but are not limited to) an individualized approach to the management of menopause and a women’s health continuum of care across the lifespan.

Support for the Global CME/CE/CPD Profession and Under-represented Healthcare Professionals
This category supports live, MAJOR national and regional conferences whose target audience includes professionals who work in, develop, implement and/or support CME/CE/CPD and QI for healthcare professionals; and live, MAJOR conferences of societies whose members include under-represented or minority healthcare professionals. NOTE: If an organization requests and receives funding through the IGLC grants portal, they are no longer eligible for funding directly from a Pfizer Country Office, or regional office.

Clinical Areas Reviewed through Joint Alliances/Partnerships
Please note, in order to apply to any of the Joint Alliance/Partnership programs listed below your organization must also meet Pfizer’s eligibility requirements. Click here to view further details about eligibility.

Chronic Pain Associated with Osteoarthritis and Chronic Low Back Pain
Pfizer and Lilly are working together on grants in support of medical education in chronic pain associated with osteoarthritis and chronic low back pain. We are committed to supporting innovative, independent medical education for healthcare professionals. All grant applications should be submitted to Pfizer only, to avoid application duplication. To apply now, go to our grant management system.

Questions? Email IGLC@pfizer.com
Diabetes Treatment
Pfizer and Merck are working together on grants in support of diabetes treatment-related education. The goal of this education is to increase the understanding of SGLT2 inhibition in the management of diabetes.

All grant applications should be submitted to Merck only. Please refer to the Merck website for information.

Nonsteroidal Anti-Androgen Treatment of Prostate
Pfizer and Astellas are working together on grants in support of prostate cancer-related education. The goal of this education is to increase the ability of healthcare professionals to consistently provide their patients with optimal guidelines-based care.

All grant applications should be submitted to Astellas only. Please refer to the Astellas website for information.

Thrombosis Prevention / Anti-coagulation
Pfizer and Bristol Myers Squibb (BMS) are working together on grants in support of thrombosis / anticoagulation-related education. The goal of this education is to decrease the unmet medical needs in the prevention and treatment of venous and arterial thrombosis.

All grant applications should be submitted to Bristol Myers Squibb only. Please refer to the Bristol Myers Squibb website for information.

Questions? Email IGLC@pfizer.com